HSE begins talks on CF drug Orkambi

News relief to patients with cystic fibrosis and families

Susan Mitchell

Deputy Editor and Health Editor @susmitchellsbp
28th August, 2016
Cystic fibrosis drug Orkambi

Negotiations between the state and the manufacturer of cystic fibrosis drug Orkambi have finally begun.

The news will be a relief to patients with cystic fibrosis and their families, who had begun to question why the health service had yet to decide whether it would seek to provide the drug – at a cost of €160,000 per patient per year.

The National Centre for Pharmacoeconomics (NCPE) recommended against funding the drug in June, but that...

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

Editorial: Our inability to agree on a model of healthcare in Ireland is unacceptable

HSE yet to cooperate with Sláintecare business case

Health Daniel Murray 1 day ago

Healthcare software developers claim they could cut waiting lists by 25%

Health Rachel Lavin 1 week ago

Tony O’Brien: The apparent slow collapse of Sláintecare deserves more than a shrug of the shoulders

Health Tony O'Brien 1 week ago